Evidence map›Paper›PMID 35327394›Full record

ArticleBiomedicines2022

An In Vivo Inflammatory Loop Potentiates KRAS Blockade.

Kristina A M Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, Christin Henning, Georgia A Giotopoulou, Mario A A Pepe, Laura V Klotz, Anne-Sophie Lamort, Rudolf A Hatz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025
    Review
  2. The current landscape of using direct inhibitors to target KRASExperimental hematology & oncology · 2023
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Kristina A M ArendtComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Giannoula NtaliardaLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 26504 Rio, Greece.ORCID 0000-0002-2299-6027
Vasileios ArmenisLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 26504 Rio, Greece.
Danai KatiLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 26504 Rio, Greece.
Christin HenningComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Georgia A GiotopoulouComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Mario A A PepeComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Laura V KlotzComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Anne-Sophie LamortComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.ORCID 0000-0001-5495-9995
Rudolf A HatzMember of the German Center for Lung Research (DZL), 35392 Gießen, Germany.
Sebastian KoboldMember of the German Center for Lung Research (DZL), 35392 Gießen, Germany.ORCID 0000-0002-5612-4673
Andrea C SchambergerComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.
Georgios T StathopoulosComprehensive Pneumology Center (CPC), Institute of Lung Health and Immunity (LHI), Helmholtz Zentrum München, 81377 Munich, Germany.ORCID 0000-0002-9215-6461
Helmholtz Zentrum München · DEUniversity of Patras · GRAsklepios Fachkliniken München-Gauting · DECenter for Integrated Protein Science Munich · DE

Funding

European Research Council 260524European Research Council 679345European Respiratory Society Romain Pauwels Research Award
6 · The paper itself

Abstract

KRAS (KRAS proto-oncogene, GTPase) inhibitors perform less well than other targeted drugs in vitro and fail clinical trials. To investigate a possible reason for this, we treated human and murine tumor cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isoprenylcysteine carboxylmethyltransferase), and AA12 (targeting KRAS

Indexed as

deltarasinIL1R1IL-1βinflammationKRASKRASG12CKRAS mutationlung cancer

Identifiers

PMID35327394
PMCPMC8945202
OpenAlexW4214825908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.